Stockscreener 앱 받기
16.82
0.36%
0.06
전일 마감가:
$16.76
열려 있는:
$16.88
하루 거래량:
128.57K
Relative Volume:
0.78
시가총액:
$703.65M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+14.97%
1개월 성능:
+36.19%
6개월 성능:
+141.32%
1년 성능:
+0.00%
1일 변동 폭
$16.14
$17.00
1주일 범위
$14.39
$17.00
52주 변동 폭
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.82 | 705.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
What makes Zenas BioPharma Inc. stock price move sharplyEarnings Beat & Technical Pattern Alert System - Newser
Sector ETF performance correlation with Zenas BioPharma Inc.2025 Price Momentum & AI Enhanced Trading Alerts - Newser
Published on: 2025-08-16 02:25:19 - Newser
Zenas BioPharma Inc.’s volatility index tracking explainedJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - Newser
Understanding Zenas BioPharma Inc.’s price movementJuly 2025 Retail & Free Reliable Trade Execution Plans - Newser
Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit - MSN
Measuring Zenas BioPharma Inc.’s beta against major indicesJuly 2025 Intraday Action & Long-Term Investment Growth Plans - Newser
Custom watchlist performance reports with Zenas BioPharma Inc.2025 Sector Review & Fast Exit/Entry Strategy Plans - Newser
Will Zenas BioPharma Inc. price bounce be sustainableDollar Strength & AI Powered Market Entry Ideas - Newser
Analyzing net buyer seller activity in Zenas BioPharma Inc.July 2025 Summary & Trade Opportunity Analysis Reports - Newser
Published on: 2025-08-15 16:40:47 - Newser
Is Zenas BioPharma Inc. a Top Dividend Stock to Watch in 2025Wall Street Watch & Verified Momentum Watchlists - Newser
Analyzing recovery setups for Zenas BioPharma Inc. investorsJuly 2025 Intraday Action & AI Enhanced Execution Alerts - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Zenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on Thursday - Defense World
Investigation announced for Investors who hold shares of Zenas - openPR.com
Buy Rating Affirmed for Zenas BioPharma: Promising Developments in Obexelimab Platform Drive Confidence - TipRanks
What Fibonacci levels say about Zenas BioPharma Inc. reboundPortfolio Return Summary & Weekly High Return Stock Opportunities - Newser
What moving averages say about Zenas BioPharma Inc.July 2025 Intraday Action & AI Enhanced Execution Alerts - Newser
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Reports Q2 2025 Financial Results - TipRanks
Forecasting Zenas BioPharma Inc. price range with options dataTen-Year Sector Performance and Summary Analysis - Newser
Press Release: Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - 富途牛牛
Zenas BioPharma Advances 3 Major Clinical Trials with $274M Cash Runway Through 2026 - Stock Titan
Zenas completes enrollment for Phase 2 trial of obexelimab for MS - Multiple Sclerosis News Today
Zenas BioPharma’s Growth Potential: Key Trials and Strategic Positioning Drive Buy Rating - TipRanks
Heatmap analysis for Zenas BioPharma Inc. and competitorsFree Watchlist for Smart Swing Trading - Newser
Zenas BioPharma Inc.’s Price Action Aligns with Quant SignalsConsistent Gain Investment Strategies Emerge - beatles.ru
Is Zenas BioPharma Inc. Stock a Smart Buy in 2025 Investment Analysis InsideVolume Confirmed Setup with Entry Confidence - Newser
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
Will Zenas BioPharma Inc. stock recover after recent drop5-Year Price Trend Summary and Analysis - Newser
How many analysts rate Zenas BioPharma Inc. as a “Buy”Get daily expert analysis on top stocks - Jammu Links News
Is Zenas BioPharma Inc. a growth stock or a value stockTriple-digit wealth increases - Jammu Links News
Zenas BioPharma Inc. Stock Analysis and ForecastInvest confidently with data-driven strategies - Jammu Links News
When is Zenas BioPharma Inc. stock expected to show significant growthUnlock exclusive trading strategies for gains - Jammu Links News
Is Zenas BioPharma Inc. a good long term investmentMaximize gains with professional stock picks - Jammu Links News
What are Zenas BioPharma Inc. company’s key revenue driversFree Daily Trading Room Entry - Jammu Links News
What are the latest earnings results for Zenas BioPharma Inc.Tremendous growth potential - Jammu Links News
Does Zenas BioPharma Inc. stock perform well during market downturnsSuperior trading gains - Jammu Links News
Is Zenas BioPharma Inc. stock overvalued or undervaluedExplosive earnings growth - Jammu Links News
Is it the right time to buy Zenas BioPharma Inc. stockMaximize portfolio value with smart investment plans - Jammu Links News
How strong is Zenas BioPharma Inc. company’s balance sheetInvest in stocks with strong fundamentals - Jammu Links News
What is the risk reward ratio of investing in Zenas BioPharma Inc. stockOutstanding capital returns - Jammu Links News
3 Highly Shorted Stocks That Could Be The Next Wall Street Sensations - Barchart.com
What are the technical indicators suggesting about Zenas BioPharma Inc.Daily Trading Guidance With Low Risk - Jammu Links News
Why is Zenas BioPharma Inc. stock attracting strong analyst attentionEntry Signal Planner To Watch Now - Jammu Links News
What is Zenas BioPharma Inc. company’s growth strategyPost Market Target Finder For Every Investor - jammulinksnews.com
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Zenas Biopharma Inc 주식 (ZBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
0.41%
0.88%
자본화:
|
볼륨(24시간):